Anti-bacterial monoclonal antibodies: back to the future?
Today's medicine has to deal with the emergence of multi-drug resistant bacteria, and is beginning to be confronted with pan-resistant microbes. This worsening inadequacy of the antibiotics concept, which has ruled infectious medicine in the last six decades creates an increasing unmet medical need that can be addressed by passive immunization. While past experience from the pre-antibiotic era with serum therapy was in many cases encouraging, antibacterial monoclonal antibodies have so far suffered high attrition rates in the clinic, generally from lack of efficacy. Yet, we believe that recent developments in a number of areas such as infectious disease pathogenesis research, translational medicine, mAb engineering, mAb manufacturing and rapid bedside diagnostics are converging to make the medium-term future permissive for antibacterial mAb development. Here, we review antibacterial mAb-based approaches that are or were in clinical development, and may potentially act as paradigms with regards to molecular targets, antibody formats and mode-of-action, pre-clinical validation and selection of most relevant patient populations, in order to increase the likelihood of successful product development in this field.
Arsanis Biosciences, Vienna, Austria.
Martin B
MB
Oleksiewicz
Gábor
G
Nagy
Eszter
E
Nagy
D000818:Animals; D000900:Anti-Bacterial Agents / Q000276:immunology* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects / Q000276:immunology*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000276:immunology; D055808:Drug Discovery / Q000379:methods; D024881:Drug Resistance, Bacterial; D006801:Humans
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal